Absence of JAK2 V617F mutation in gastric cancers [7]

Acta Oncologica

Volumn 45, Issue 2, 2006, Pages 222-223

  Jong, Woo Lee ^a   Young, Hwa Soung ^a   Su, Young Kim ^a   Suk, Woo Nam ^a   Won, Sang Park ^a   Jung, Young Lee ^a   Nam, Jin Yoo ^a   Sug, Hyung Lee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; GEFITINIB; IMATINIB; JANUS KINASE 2; JANUS KINASE INHIBITOR; TRASTUZUMAB;

ADVANCED CANCER; BREAST CANCER; CANCER THERAPY; CELL GROWTH; CELL SURVIVAL; COLON CANCER; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; LUNG CANCER; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; THROMBOCYTOPENIA;

HUMANS; JANUS KINASE 2; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; STOMACH NEOPLASMS;

EID: 33645109756     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500341223     Document Type: Letter

References (5)

1. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002;296:1653-5.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
4. To KF, Chan MW, Leung WK, Ng EK, Yu J, Bai AH, et al. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. Br J Cancer 2004;91:1335-41.
5. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.